Cemdomespib (KU-596) 是一种高效的二代HSP90调节剂。Cemdomespib 具有改善糖尿病周围神经病变模型感觉缺陷的功效。Cemdomespib 通过诱导热休克反应诱导 HSP70 水平并表现出神经保护活性。

Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response [1] [2] [3].

After 8 weeks of diabetes, Cemdomespib (KU-596; 2, 10, or 20 mg/kg; i.p.; administered for 6 weeks via a once per week) dose-dependently reverses the pre-existing psychosensory deficits. Cemdomespib also dose-dependently prevents the diabetes-induced deficits in motor (MNCV) and sensory (SNCV) nerve conduction velocities [1]. Cemdomespib (20 mg/kg; oral gavage once per week for 4 weeks) significantly reverses the sensory hypoalgesia in WT mice but not the Hsp70 KO mice [1]. Animal Model: Diabetic Swiss Webster mice [1] Dosage: 2, 10, or 20 mg/kg Administration: Administered after 8 weeks of diabetes via once per week intra-peritoneal injections. Result: Improved diabetes induced hypoalgesia and sensory neuron bioenergetic deficits in a dose-dependent manner.

1450642-92-8

C24H30FNO6

447.5

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years